GSA Capital Partners LLP cut its stake in shares of Ophthotech Corp (NASDAQ:OPHT) by 45.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 121,048 shares of the biopharmaceutical company’s stock after selling 102,201 shares during the quarter. GSA Capital Partners LLP owned approximately 0.33% of Ophthotech worth $330,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently made changes to their positions in OPHT. Acadian Asset Management LLC acquired a new position in Ophthotech during the 2nd quarter worth about $3,179,000. Municipal Employees Retirement System of Michigan acquired a new position in Ophthotech during the 1st quarter worth about $1,051,000. Dimensional Fund Advisors LP lifted its holdings in Ophthotech by 202.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 563,271 shares of the biopharmaceutical company’s stock worth $1,543,000 after buying an additional 377,267 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Ophthotech by 80.6% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 739,987 shares of the biopharmaceutical company’s stock worth $2,020,000 after acquiring an additional 330,226 shares in the last quarter. Finally, Spark Investment Management LLC raised its position in shares of Ophthotech by 65.8% in the 1st quarter. Spark Investment Management LLC now owns 428,700 shares of the biopharmaceutical company’s stock worth $1,174,000 after acquiring an additional 170,200 shares in the last quarter. 56.17% of the stock is currently owned by hedge funds and other institutional investors.
OPHT stock opened at $2.33 on Friday. Ophthotech Corp has a 1-year low of $2.25 and a 1-year high of $4.50. The stock has a market capitalization of $87.24 million, a PE ratio of 0.74 and a beta of 1.32.
Ophthotech (NASDAQ:OPHT) last posted its quarterly earnings data on Wednesday, August 1st. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.39) by $0.02. research analysts predict that Ophthotech Corp will post -1.55 earnings per share for the current year.
Several research analysts have recently weighed in on the company. ValuEngine lowered Ophthotech from a “sell” rating to a “strong sell” rating in a research report on Tuesday, September 4th. Chardan Capital reissued a “hold” rating and issued a $4.00 price objective on shares of Ophthotech in a research report on Thursday, August 2nd. Finally, Zacks Investment Research lowered Ophthotech from a “buy” rating to a “hold” rating in a research report on Tuesday, July 10th. Two research analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. Ophthotech currently has an average rating of “Hold” and a consensus target price of $3.50.
Ophthotech Corporation, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases, with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, for dry and wet forms of age-related macular degeneration, a disorder of the central portion of the retina known as the macula.
Featured Story: Google Finance
Want to see what other hedge funds are holding OPHT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ophthotech Corp (NASDAQ:OPHT).
Receive News & Ratings for Ophthotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ophthotech and related companies with MarketBeat.com’s FREE daily email newsletter.